Literature DB >> 6417077

Effect of intravenous dopamine on hypercapnic ventilatory response in humans.

D S Ward, J W Bellville.   

Abstract

This study assessed the effect of low-dose intravenous dopamine (3 micrograms X kg-1 X min-1) on the hypercapnic ventilatory response in humans. Six normal healthy subjects were studied. By manipulating the inspired carbon dioxide concentration, the end-tidal carbon dioxide tension was raised in a stepwise fashion from 41 to 49 Torr and held at this level for 4 min. The end-tidal CO2 tension was then lowered back to 41 Torr in a stepwise fashion. The end-tidal O2 tension was held constant at 106 Torr throughout the experiment. The ventilatory response to this normoxic hypercapnic stimulus was analyzed by fitting two exponential functions, allowing the response to be separated into slow and fast chemoreflex loops. Each loop is described by a gain, time constant, and time delay. A single eupneic threshold was used for both loops. Nine control experiments and eight experiments performed during dopamine infusion were analyzed. The dopamine infusion caused the fast loop gain to be significantly (P less than 0.05) reduced from 0.64 to 0.19 l X min-1 X Torr-1, while the slow loop gain was unchanged. The fast loop contribution was reduced from 28 to 11% of the total ventilatory response. None of the other model parameters were significantly affected by the dopamine infusion. Exogenously administered dopamine substantially reduces the sensitivity of the fast chemoreflex loop to carbon dioxide.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6417077     DOI: 10.1152/jappl.1983.55.5.1418

Source DB:  PubMed          Journal:  J Appl Physiol Respir Environ Exerc Physiol        ISSN: 0161-7567


  11 in total

1.  Effect of exogenous dopamine on the hypercapnic ventilatory response in cats during normoxia.

Authors:  A Berkenbosch; J DeGoede; C N Olievier; D S Ward
Journal:  Pflugers Arch       Date:  1986-11       Impact factor: 3.657

2.  On a pseudo-rebreathing technique to assess the ventilatory sensitivity to carbon dioxide in man.

Authors:  A Dahan; A Berkenbosch; J DeGoede; I C Olievier; J G Bovill
Journal:  J Physiol       Date:  1990-04       Impact factor: 5.182

3.  Evidence for interaction between the contributions to ventilation from the central and peripheral chemoreceptors in man.

Authors:  P A Robbins
Journal:  J Physiol       Date:  1988-07       Impact factor: 5.182

4.  A pseudo-rebreathing technique for assessing the ventilatory response to carbon dioxide in cats.

Authors:  A Berkenbosch; J DeGoede; C N Olievier; J J Schuitmaker
Journal:  J Physiol       Date:  1986-12       Impact factor: 5.182

5.  The influence of oxygen on the ventilatory response to carbon dioxide in man.

Authors:  A Dahan; J DeGoede; A Berkenbosch; I C Olievier
Journal:  J Physiol       Date:  1990-09       Impact factor: 5.182

6.  The ventilatory CO2 sensitivities from Read's rebreathing method and the steady-state method are not equal in man.

Authors:  A Berkenbosch; J G Bovill; A Dahan; J DeGoede; I C Olievier
Journal:  J Physiol       Date:  1989-04       Impact factor: 5.182

7.  Onset responses of ventilation and cerebral blood flow to hypercapnia in humans: rest and exercise.

Authors:  Shigehiko Ogoh; Philip N Ainslie; Tadayoshi Miyamoto
Journal:  J Appl Physiol (1985)       Date:  2009-01-08

8.  Interindividual variability in the dose-specific effect of dopamine on carotid chemoreceptor sensitivity to hypoxia.

Authors:  Jacqueline K Limberg; Blair D Johnson; Walter W Holbein; Sushant M Ranadive; Michael T Mozer; Michael J Joyner
Journal:  J Appl Physiol (1985)       Date:  2015-11-19

9.  Validity of urinary monoamine assay sales under the "spot baseline urinary neurotransmitter testing marketing model".

Authors:  Marty Hinz; Alvin Stein; Thomas Uncini
Journal:  Int J Nephrol Renovasc Dis       Date:  2011-07-20

10.  The Parkinson's disease death rate: carbidopa and vitamin B6.

Authors:  Marty Hinz; Alvin Stein; Ted Cole
Journal:  Clin Pharmacol       Date:  2014-10-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.